Carlos Villar-Gosalvez, MD
Family Medicine · Cullman, ALNPI 1548422868
Payments from drug & device makers
Across 334 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$859
- AstraZeneca$773
- Novo Nordisk$662
- Amgen$433
- Otsuka America Pharmaceutical, Inc.$430
- GSK$367
- plus $3K from 33 others
What the payments were for
- Food & beverage$6,286100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $859 |
| AstraZeneca | 31 | $773 |
| Novo Nordisk | 35 | $662 |
| Amgen | 18 | $433 |
| Otsuka America Pharmaceutical, Inc. | 21 | $430 |
| GSK | 24 | $367 |
| Bayer | 17 | $321 |
| Abbott | 14 | $321 |
| Lilly USA, LLC | 16 | $265 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $254 |
| Axsome Therapeutics, Inc. | 10 | $213 |
| Exact Sciences | 8 | $160 |
| Harmony Biosciences LLC | 3 | $105 |
| Merck | 6 | $104 |
| Jazz Pharmaceuticals Inc. | 4 | $94 |
| Dexcom, Inc. | 5 | $89 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $87 |
| Paratek Pharmaceuticals, Inc. | 4 | $78 |
| Pfizer | 4 | $77 |
| Boehringer Ingelheim | 3 | $59 |
| Organogenesis Inc. | 2 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Inspire Medical Systems, Inc. | 1 | $41 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Urgo Medical North America, LLC | 1 | $30 |
| Integra Lifesciences Corporation | 1 | $25 |
| Kerecis Limited | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Medtronic | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $21 |
| Mylan Specialty L.p. | 1 | $18 |
| Smith+Nephew | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $15 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,286 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $110,509 |
| OzempicSemaglutide | 72 | $93,226 |
| VraylarCariprazine Hcl | 53 | $80,115 |
| TrulicityDulaglutide | 52 | $79,574 |
| MounjaroTirzepatide | 53 | $62,299 |
| RybelsusSemaglutide | 44 | $58,983 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $49,611 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $41,548 |
| FarxigaDapagliflozin Propanediol | 41 | $36,846 |
| XareltoRivaroxaban | 49 | $34,587 |
| JardianceEmpagliflozin | 27 | $31,863 |
| JanuviaSitagliptin Phosphate | 25 | $23,817 |
| LinzessLinaclotide | 29 | $20,426 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $20,152 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $15,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $662 | $152,209116 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $265 | $141,873105 claims |
| PfizerEliquis, Premarin | $77 | $118,312116 claims |
| AbbVieVraylar, Linzess | $859 | $100,54182 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $367 | $64,13977 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $773 | $61,34277 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $59 | $40,95044 claims |
| Johnson & JohnsonXarelto | $22 | $34,58749 claims |
| MerckJanuvia | $104 | $23,81725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Cullman
- Randall QuinnCullman$5.4M
- Ben BostickCullman$1.5M
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.